Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE versus MULTAQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE versus MULTAQ.
DRONEDARONE vs MULTAQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
400 mg orally twice daily after meals
400 mg orally twice daily with morning and evening meals.
None Documented
None Documented
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic